L
Louise A. Knight
Researcher at Queen Alexandra Hospital
Publications - 24
Citations - 708
Louise A. Knight is an academic researcher from Queen Alexandra Hospital. The author has contributed to research in topics: Chemosensitivity assay & Cisplatin. The author has an hindex of 16, co-authored 24 publications receiving 663 citations. Previous affiliations of Louise A. Knight include University of Portsmouth.
Papers
More filters
Journal ArticleDOI
Cancer cell adaptation to chemotherapy.
Federica Di Nicolantonio,Stuart Mercer,Louise A. Knight,Francis G Gabriel,Pauline A. Whitehouse,Sanjay Sharma,Augusta Fernando,Sharon Glaysher,Silvana Di Palma,Penny Johnson,Shaw Somers,Simon Toh,Bernard Higgins,Alan Lamont,Tim J. Gulliford,Jeremy Hurren,Constantinos Yiangou,Ian A. Cree +17 more
TL;DR: It is suggested that up-regulation of resistance genes or down-regulation in target genes may occur rapidly in human solid tumors, within days of the start of treatment, and that similar changes are present in pre- and post-chemotherapy biopsy material.
Journal ArticleDOI
Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma.
Sanjay Sharma,Michael H Neale,Federica Di Nicolantonio,Louise A. Knight,Pauline A. Whitehouse,Stuart Mercer,Bernard Higgins,Alan Lamont,Richard H. Osborne,Andrew C Hindley,Christian M. Kurbacher,Ian A. Cree +11 more
TL;DR: The results show similar response rates to previous studies using ATP-TCA directed therapy in recurrent ovarian cancer, and the assay shows high evaluability and adds weight to the reproducibility of results from different centres.
Journal ArticleDOI
The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours
Louise A. Knight,Federica Di Nicolantonio,Pauline A. Whitehouse,Stuart Mercer,Sanjay Sharma,Sharon Glaysher,Penny Johnson,Ian A. Cree +7 more
TL;DR: The in vitro model suggests that gefitinib may have differential effects in response to concomitant cytotoxic chemotherapy with the agents tested during this study, and represents the first use of a TKI in the assay.
Journal ArticleDOI
The effect of pentamidine on melanoma ex vivo.
Jason Smith,Benjamin J. Stewart,Sharon Glaysher,Katharine Peregrin,Louise A. Knight,David J. Weber,Ian A. Cree +6 more
TL;DR: Results show that pentamidine has activity against melanoma, and support the prospect of its development for therapeutic use.
Journal ArticleDOI
Heterogeneity of chemosensitivity of colorectal adenocarcinoma determined by a modified ex vivo ATP-tumor chemosensitivity assay (ATP-TCA).
Pauline A. Whitehouse,Louise A. Knight,Federica Di Nicolantonio,Stuart Mercer,Sanjay Sharma,Ian A. Cree +5 more
TL;DR: The degree of heterogeneity demonstrated from these results suggests that the ATP-TCA could be used to identify patients who might benefit from specific chemotherapeutic agents alone or in combination.